SCHEMBL1471497

SCHEMBL1471497

CC(C)Oc1ccccc1SCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.52
NPC1 O15118 3/20 0.52
CASP3 P42574 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.48
GAA P10253 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45
TSHR P16473 2/20 0.45
HPGD P15428 2/20 0.45
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.43
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6564387 0.76 RAB9A (0.67) RAB9ANPC1SMN1; SMN2L3MBTL1MEN1
SCHEMBL1470962 0.75 RAB9A (0.57) RAB9ANPC1SMN1; SMN2L3MBTL1MEN1
SCHEMBL12750162 0.75 PTGS2 (0.57) ALDH1A1
SCHEMBL1471437 0.74 NPC1 (0.61) RAB9ANPC1CASP3SMN1; SMN2SENP8
SCHEMBL1471007 0.73 IRAK4 (0.41) ALDH1A1
SCHEMBL10421957 0.70 RAB9A (1.00) RAB9ANPC1CASP3SMN1; SMN2SENP8
SCHEMBL6343040 0.69 ADRA1A (0.66) MEN1KMT2ATSHRHPGDCYP1A2
SCHEMBL6565574 0.69 L3MBTL1 (0.59) RAB9ANPC1L3MBTL1MEN1KMT2A
SCHEMBL1307183 0.69 NPC1 (0.62) RAB9ANPC1CASP3SMN1; SMN2SENP8
SCHEMBL12459480 0.68 L3MBTL1 (0.58) RAB9ANPC1CASP3SMN1; SMN2SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915420-B2 Aryl piperidine amides JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-20080009521-A1 Aryl Piperidine Amides HUANG CHARLES Q 2008-01-10 US disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
EP-1660472-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
WO-2005021525-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-10 WO disclosed
US-20050049239-A1 Aryl piperidine amides JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009521-A1 Aryl Piperidine Amides BDNF, NTRK2, OPRL1 RAB9A 3100/4885NPC1 514/4885CASP3 3028/4885
US-20050049239-A1 Aryl piperidine amides BDNF, NTRK2, OPRL1 RAB9A 3100/4885NPC1 514/4885CASP3 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.